Literature DB >> 27956576

Tripartite Motif 8 Contributes to Pathological Cardiac Hypertrophy Through Enhancing Transforming Growth Factor β-Activated Kinase 1-Dependent Signaling Pathways.

Lijuan Chen1, Jia Huang2, Yan-Xiao Ji2, Fanghua Mei2, Pi-Xiao Wang2, Ke-Qiong Deng2, Xi Jiang2, Genshan Ma2, Hongliang Li1.   

Abstract

Tripartite motif (TRIM) 8 functions as an E3 ubiquitin ligase, interacting with and ubiquitinating diverse substrates, and is implicated in various pathological processes. However, the function of TRIM8 in the heart remains largely uncharacterized. This study aims to explore the role of TRIM8 in the development of pathological cardiac hypertrophy. Mice and isolated neonatal rat cardiomyocytes overexpressing or lacking TRIM8 were examined in several experiments. The effect of aortic banding-induced cardiac hypertrophy was analyzed by echocardiographic, pathological and molecular analyses. Our results indicated that the TRIM8 overexpression in hearts exacerbated the cardiac hypertrophy triggered by aortic banding. In contrast, the development of pathological cardiac hypertrophy was profoundly blocked in TRIM8-deficient hearts. Mechanistically, our study suggests that TRIM8 may elicit cardiodetrimental effects by promoting the activation of transforming growth factor β-activated kinase 1 (TAK1)-p38/JNK signaling pathways. Similar results were observed in cultured neonatal rat cardiomyocytes treated with angiotensin II. The rescue experiments using the TAK1-specific inhibitor 5z-7-ox confirmed the requirement of TAK1 activation in TRIM8-mediated pathological cardiac hypertrophy. Furthermore, TRIM8 contributed to TAK1 activation by binding to and promoting TAK1 ubiquitination. In conclusion, our study demonstrates that TRIM8 plays a deleterious role in pressure overload-induced cardiac hypertrophy by accelerating the activation of TAK1-dependent signaling pathways.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  MAP kinase signaling system; angiotensin II; cardiomegaly; myocytes, cardiac; ubiquitination

Mesh:

Substances:

Year:  2016        PMID: 27956576     DOI: 10.1161/HYPERTENSIONAHA.116.07741

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  18 in total

1.  ANGPTL8 is a negative regulator in pathological cardiac hypertrophy.

Authors:  Lin Hu; Jiarui Wei; Yue Zhang; Ziyuan Wang; Junming Tang; Jian Tang; Yujiu Gao; Xiaoqiao Zhang; Yifan Li; Yantong Liu; Shinan Ma; Xingrong Guo; Qiufang Zhang
Journal:  Cell Death Dis       Date:  2022-07-18       Impact factor: 9.685

2.  TGFβ (Transforming Growth Factor-Beta)-Activated Kinase 1 Regulates Arteriovenous Fistula Maturation.

Authors:  Haidi Hu; Shin-Rong Lee; Hualong Bai; Jianming Guo; Takuya Hashimoto; Toshihiko Isaji; Xiangjiang Guo; Tun Wang; Katharine Wolf; Shirley Liu; Shun Ono; Bogdan Yatsula; Alan Dardik
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-05-28       Impact factor: 8.311

3.  Exacerbation of diabetic cardiac hypertrophy in OVE26 mice by angiotensin II is associated with JNK/c-Jun/miR-221-mediated autophagy inhibition.

Authors:  Ling-Bo Qian; Sai-Zhi Jiang; Xiao-Qiang Tang; Jian Zhang; Ya-Qin Liang; Hai-Tao Yu; Jing Chen; Zheng Xu; Rui-Ming Liu; Bradley B Keller; Hong-Lei Ji; Lu Cai
Journal:  Oncotarget       Date:  2017-09-28

4.  Tollip Negatively Regulates Vascular Smooth Muscle Cell-Mediated Neointima Formation by Suppressing Akt-Dependent Signaling.

Authors:  Hong Zhi; Fu-Han Gong; Wen-Lin Cheng; Kongbo Zhu; Long Chen; Yuyu Yao; Xingzhou Ye; Xue-Yong Zhu; Hongliang Li
Journal:  J Am Heart Assoc       Date:  2018-06-10       Impact factor: 5.501

Review 5.  The role of post-translational modifications in cardiac hypertrophy.

Authors:  Kaowen Yan; Kun Wang; Peifeng Li
Journal:  J Cell Mol Med       Date:  2019-04-04       Impact factor: 5.310

6.  Tripartite Motif 8 Deficiency Relieves Hepatic Ischaemia/reperfusion Injury via TAK1-dependent Signalling Pathways.

Authors:  Qiu Tao; Wang Tianyu; Zhou Jiangqiao; Chen Zhongbao; Ma Xiaoxiong; Zhang Long; Zou Jilin
Journal:  Int J Biol Sci       Date:  2019-06-04       Impact factor: 6.580

7.  Tripartite motif 10 regulates cardiac hypertrophy by targeting the PTEN/AKT pathway.

Authors:  Hui Yang; Xiao-Xiao Wang; Chun-Yu Zhou; Xue Xiao; Cui Tian; Hui-Hua Li; Chun-Lin Yin; Hong-Xia Wang
Journal:  J Cell Mol Med       Date:  2020-04-28       Impact factor: 5.310

Review 8.  The role of K63-linked polyubiquitination in cardiac hypertrophy.

Authors:  Kaowen Yan; Murugavel Ponnusamy; Ying Xin; Qi Wang; Peifeng Li; Kun Wang
Journal:  J Cell Mol Med       Date:  2018-08-13       Impact factor: 5.310

9.  Bakuchiol protects against pathological cardiac hypertrophy by blocking NF-κB signaling pathway.

Authors:  Zheng Wang; Lu Gao; Lili Xiao; Lingyao Kong; Huiting Shi; Xinyu Tian; Luosha Zhao
Journal:  Biosci Rep       Date:  2018-10-31       Impact factor: 3.840

10.  Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway.

Authors:  Hai-Han Liao; Nan Zhang; Yan-Yan Meng; Hong Feng; Jing-Jing Yang; Wen-Jin Li; Si Chen; Hai-Ming Wu; Wei Deng; Qi-Zhu Tang
Journal:  Oxid Med Cell Longev       Date:  2019-12-06       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.